Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 432

1.

Magnetic resonance imaging for detection and determination of tumor volume in a genetically engineered mouse model of ovarian cancer.

Hensley H, Quinn BA, Wolf RL, Litwin SL, Mabuchi S, Williams SJ, Williams C, Hamilton TC, Connolly DC.

Cancer Biol Ther. 2007 Nov;6(11):1717-25. Epub 2007 Aug 3.

PMID:
17986851
[PubMed - indexed for MEDLINE]
Free Article
2.

Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.

Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC.

Cancer Res. 2003 Mar 15;63(6):1389-97.

PMID:
12649204
[PubMed - indexed for MEDLINE]
Free Article
3.

Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.

Pieretti-Vanmarcke R, Donahoe PK, Szotek P, Manganaro T, Lorenzen MK, Lorenzen J, Connolly DC, Halpern EF, MacLaughlin DT.

Clin Cancer Res. 2006 Mar 1;12(5):1593-8.

PMID:
16533786
[PubMed - indexed for MEDLINE]
Free Article
4.

Magnetic resonance imaging of the natural history of in situ mammary neoplasia in transgenic mice: a pilot study.

Jansen SA, Conzen SD, Fan X, Markiewicz EJ, Newstead GM, Karczmar GS.

Breast Cancer Res. 2009;11(5):R65. doi: 10.1186/bcr2357. Epub .

PMID:
19732414
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Development of a syngeneic mouse model of epithelial ovarian cancer.

Quinn BA, Xiao F, Bickel L, Martin L, Hua X, Klein-Szanto A, Connolly DC.

J Ovarian Res. 2010 Oct 19;3:24. doi: 10.1186/1757-2215-3-24.

PMID:
20958993
[PubMed]
Free PMC Article
6.

An orthotopic model of serous ovarian cancer in immunocompetent mice for in vivo tumor imaging and monitoring of tumor immune responses.

Nunez-Cruz S, Connolly DC, Scholler N.

J Vis Exp. 2010 Nov 28;(45). pii: 2146. doi: 10.3791/2146.

PMID:
21178956
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Müllerian inhibiting substance type II receptor (MISIIR): a novel, tissue-specific target expressed by gynecologic cancers.

Bakkum-Gamez JN, Aletti G, Lewis KA, Keeney GL, Thomas BM, Navarro-Teulon I, Cliby WA.

Gynecol Oncol. 2008 Jan;108(1):141-8. Epub 2007 Nov 7.

PMID:
17988723
[PubMed - indexed for MEDLINE]
8.

A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model.

Wirtzfeld LA, Wu G, Bygrave M, Yamasaki Y, Sakai H, Moussa M, Izawa JI, Downey DB, Greenberg NM, Fenster A, Xuan JW, Lacefield JC.

Cancer Res. 2005 Jul 15;65(14):6337-45.

PMID:
16024636
[PubMed - indexed for MEDLINE]
Free Article
9.

Dynamic contrast-enhanced magnetic resonance imaging of tumors: preclinical validation of parametric images.

Egeland TA, Simonsen TG, Gaustad JV, Gulliksrud K, Ellingsen C, Rofstad EK.

Radiat Res. 2009 Sep;172(3):339-47. doi: 10.1667/RR1787.1.

PMID:
19708783
[PubMed - indexed for MEDLINE]
10.

Development of cystic glandular hyperplasia of the endometrium in Mullerian inhibitory substance type II receptor-pituitary tumor transforming gene transgenic mice.

El-Naggar SM, Malik MT, Martin A, Moore JP, Proctor M, Hamid T, Kakar SS.

J Endocrinol. 2007 Jul;194(1):179-91.

PMID:
17592032
[PubMed - indexed for MEDLINE]
Free Article
11.

Combined in vivo molecular and anatomic imaging for detection of ovarian carcinoma-associated protease activity and integrin expression in mice.

Hensley HH, Roder NA, O'Brien SW, Bickel LE, Xiao F, Litwin S, Connolly DC.

Neoplasia. 2012 Jun;14(6):451-62.

PMID:
22787427
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Generation of tumors in transgenic mice expressing the SV40 T antigen under the control of ovarian-specific promoter 1.

Garson K, Macdonald E, Dubé M, Bao R, Hamilton TC, Vanderhyden BC.

J Soc Gynecol Investig. 2003 May;10(4):244-50.

PMID:
12759154
[PubMed - indexed for MEDLINE]
13.

Cyclooxygenase-1 is overexpressed in multiple genetically engineered mouse models of epithelial ovarian cancer.

Daikoku T, Tranguch S, Trofimova IN, Dinulescu DM, Jacks T, Nikitin AY, Connolly DC, Dey SK.

Cancer Res. 2006 Mar 1;66(5):2527-31.

PMID:
16510568
[PubMed - indexed for MEDLINE]
Free Article
14.

Detection and volume determination of colonic tumors in Min mice by magnetic resonance micro-imaging.

Hensley HH, Chang WC, Clapper ML.

Magn Reson Med. 2004 Sep;52(3):524-9.

PMID:
15334570
[PubMed - indexed for MEDLINE]
16.

Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha.

Franco F, Thomas GD, Giroir B, Bryant D, Bullock MC, Chwialkowski MC, Victor RG, Peshock RM.

Circulation. 1999 Jan 26;99(3):448-54.

PMID:
9918534
[PubMed - indexed for MEDLINE]
Free Article
17.

High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-alpha-subunit promoter/Simian virus 40 T-antigen fusion gene.

Mikola M, Kero J, Nilson JH, Keri RA, Poutanen M, Huhtaniemi I.

Oncogene. 2003 May 22;22(21):3269-78.

PMID:
12761497
[PubMed - indexed for MEDLINE]
18.

Magnetic resonance imaging-based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response.

Klostergaard J, Auzenne E, Ghosh S, Farquhar D, Rivera B, Price RE.

Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:111-7.

PMID:
16515577
[PubMed - indexed for MEDLINE]
19.

Comparison of tumor blood perfusion assessed by dynamic contrast-enhanced MRI with tumor blood supply assessed by invasive imaging.

Graff BA, Benjaminsen IC, Brurberg KG, Ruud EB, Rofstad EK.

J Magn Reson Imaging. 2005 Mar;21(3):272-81.

PMID:
15723369
[PubMed - indexed for MEDLINE]
20.

Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants.

Chin J, Kadhim S, Garcia B, Kim YS, Karlik S.

J Urol. 1991 Jun;145(6):1297-301.

PMID:
2033720
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk